Synthesis and Biological Activity of a Novel Series of 6-Substituted Thieno[2,3-d]pyrimidine Antifolate Inhibitors of Purine Biosynthesis with Selectivity for High Affinity Folate Receptors over the Reduced Folate Carrier and Proton-Coupled Folate Transporter for Cellular Entry

被引:72
作者
Deng, Yijun [1 ]
Zhou, Xilin [2 ]
Desmoulin, Sita Kugel [1 ]
Wu, Jianmei [4 ]
Cherian, Christina [4 ]
Hou, Zhanjun [4 ]
Matherly, Larry H. [1 ,3 ,4 ]
Gangjee, Aleem [2 ]
机构
[1] Wayne State Univ, Sch Med, Grad Program Canc Biol, Detroit, MI 48201 USA
[2] Duquesne Univ, Grad Sch Pharmaceut Sci, Div Med Chem, Pittsburgh, PA 15282 USA
[3] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA
[4] Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, Detroit, MI 48201 USA
基金
美国国家卫生研究院;
关键词
THYMIDYLATE SYNTHASE INHIBITOR; POTENT INHIBITOR; IN-VITRO; METHOTREXATE; DERIVATIVES; ANTIMETABOLITE; CYTOTOXICITY; IMPACT; AGENTS;
D O I
10.1021/jm8011323
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of seven 2-amino4-oxo-6-substituted thieno[2,3-d]pyrimidines with bridge length variations (from 2 to 8 carbon atoms) were synthesized as selective folate receptor (FR) alpha and beta substrates and as antitumor agents. The syntheses were accomplished from appropriate allylalcohols and 4-iodobenzoate to afford the aldehydes, which were converted to the appropriate 2-amino-4-carbethoxy-5-substituted thiophenes 23-29. Cyclization with chloroformamidine afforded the thieno[2,3-d]pyrimidines 30-36, which were hydrolyzed and coupled with diethyl-L-glutamate, followed by saponification, to give the target compounds 2-8. Compounds 3-6 were potent growth inhibitors (IC50 4.7-334 nM) of human tumor cells (KB and IGROV1) that express FRs. In addition, compounds 3-6 inhibited the growth of Chinese hamster ovary (CHO) cells that expressed FRs but not the reduced folate carrier (RFC) or proton-coupled folate transporter (PCFT). However, the compounds were inactive toward CHO cells that lacked FRs but contained either the RFC or PCFT. By nucleoside and 5-amino-imidazole carboxamide (AICA) protection studies, along with in vitro and in situ enzyme activity assays, the mechanism of antitumor activity was identified as the dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, AICA ribonucleotide formyltransferase. The dual inhibitory activity of the active thieno[2,3-d]pyrimidine antifolates and the FR specificity represent unique mechanistic features for these compounds distinct from all other known antifolates. The potent inhibitory effects of compounds 3-6 toward cells expressing FRs but not PCFT provide direct evidence that cellular uptake of this series of compounds by FRs does not depend on the presence of PCFT and argues that direct coupling between these transporters is not obligatory.
引用
收藏
页码:2940 / 2951
页数:12
相关论文
共 40 条
[21]   PREPARATION + ANTITUMOR PROPERTIES OF ACYLATED DERIVATIVES OF 6-THIOPURINE RIBOSIDES [J].
LEWIS, LR ;
ROBINS, RK ;
CHENG, CC .
JOURNAL OF MEDICINAL CHEMISTRY, 1964, 7 (02) :200-&
[22]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265
[23]   Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells [J].
Lu, Yanhui ;
Wu, Jun ;
Wu, Jianmei ;
Gonit, Mefsin ;
Yang, Xiaojuan ;
Lee, Alice ;
Xiang, Guangya ;
Li, Hong ;
Liu, Shujun ;
Marcucci, Guido ;
Ratnam, Manohar ;
Lee, Robert J. .
MOLECULAR PHARMACEUTICS, 2007, 4 (05) :707-712
[24]   Human reduced folate carrier: translation of basic biology to cancer etiology and therapy [J].
Matherly, Larry H. ;
Hou, Zhanjun ;
Deng, Yijun .
CANCER AND METASTASIS REVIEWS, 2007, 26 (01) :111-128
[25]   Membrane transport of folates [J].
Matherly, LH ;
Goldman, D .
VITAMINS AND HORMONES - ADVANCES IN RESEARCH AND APPLICATIONS, VOL 66, 2003, 66 :403-456
[26]   Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo [J].
Mauritz, Robert ;
Peters, Godefridus J. ;
Kathmann, Ietje ;
Teshale, Habte ;
Noordhuis, Paul ;
Comijn, Elizabeth M. ;
Pinedo, Herbert M. ;
Jansen, Gerrit .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (06) :937-948
[27]  
MONAHAN BP, 2001, CANC CHEMOTHERAPY BI, P109
[28]   SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate [J].
Mueller, Cristina ;
Forrer, Flavio ;
Schibli, Roger ;
Krenning, Eric P. ;
de Jong, Marion .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (02) :310-317
[29]   PHASE-I STUDY OF (6R)-5,10-DIDEAZATETRAHYDROFOLATE - A FOLATE ANTIMETABOLITE INHIBITORY TO DE-NOVO PURINE SYNTHESIS [J].
RAY, MS ;
MUGGIA, FM ;
LEICHMAN, CG ;
GRUNBERG, SM ;
NELSON, RL ;
DYKE, RW ;
MORAN, RG .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (14) :1154-1159
[30]   2,4-DIAMINOTHIENO [2,3-D] PYRIMIDINES AS ANTIFOLATES AND ANTIMALARIALS .3. SYNTHESIS OF 5,6-DISUBSTITUTED DERIVATIVES AND RELATED TETRACYCLIC ANALOGS [J].
ROSOWSKY, A ;
CHEN, KKN ;
LIN, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1973, 16 (03) :191-194